Product DevelopmentBNGO is enhancing its product line by rolling out new laboratory-developed tests for pan-hematological malignancies and genetic diseases from its CLIA lab.

Regulatory ProgressSignificant progress has been made on OGM reimbursement with the acquisition of a CPT code from the American Medical Association for use in cytogenomic genome-wide analysis.

Technology AdvancementsThe continued rollout and upgrade cycle of BNGO's next-generation, higher-throughput Stratys system is set to drive growth.

Bears Say

Financial PerformanceBNGO experienced significant declines in its instrument and services lines.

Revenue GuidanceBNGO again reduced its 2024 revenue guide to $28-30M, below its prior $32-36M, $36-40M, and $37-41M guides earlier this year.

Workforce ReductionBionano will part ways with another 45% of its workforce, expected to reduce its annual cash burn by an additional $25-30M.

---

Financials

Annual

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.32% Insiders

1.86% Mutual Funds

<0.01% Other Institutional Investors

96.48% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

Website Traffic

Sorry, No Data Available

There is no website visitor data available for this stock.

---

BNGO FAQ

What was Bionano Genomics’s price range in the past 12 months?

Bionano Genomics lowest stock price was $0.18 and its highest was $1.40 in the past 12 months.

What is Bionano Genomics’s market cap?

Bionano Genomics’s market cap is $28.73M.

When is Bionano Genomics’s upcoming earnings report date?

Bionano Genomics’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.

How were Bionano Genomics’s earnings last quarter?

Bionano Genomics released its earnings results on Nov 13, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.198 by -$0.322.

Is Bionano Genomics overvalued?

According to Wall Street analysts Bionano Genomics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bionano Genomics pay dividends?

Bionano Genomics does not currently pay dividends.

What is Bionano Genomics’s EPS estimate?

Bionano Genomics’s EPS estimate is -0.14.

How many shares outstanding does Bionano Genomics have?

Bionano Genomics has 139,824,250 shares outstanding.

What happened to Bionano Genomics’s price movement after its last earnings report?

Bionano Genomics reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.198. Following the earnings report the stock price went down -7.143%.

Which hedge fund is a major shareholder of Bionano Genomics?

Among the largest hedge funds holding Bionano Genomics’s share is GMT Capital Corp. It holds Bionano Genomics’s shares valued at 240K.

---

BioNano Genomics Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-161.77%

Trailing 12-Months

Asset Growth

-51.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bionano Genomics

BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.

---

BNGO Earnings Call

Q3 2024

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a challenging financial quarter for Bionano, with significant revenue decline and negative gross margins. However, there are positive signs of operational improvement, particularly in cost reductions, increased consumable sales, and progress in clinical research and reimbursement initiatives. The sentiment is mixed with positive strides in some areas countered by financial setbacks.Read More>

---